IgG Light Chain Secretory Leader Engineering to Prevent N-Terminal Truncation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The production of therapeutic monoclonal antibodies (mAbs) is hindered by N-terminal truncation of IgG light chains, leading to impurities and batch-to-batch variability, which are difficult to detect and remove, affecting product quality and safety.
Innovation Solution
Alter the nascent N-terminal sequence of IgG light chains by replacing the standard murine leader sequence with alternative sequences such as V-lambda or kappa leader sequences or modifying the first three amino acids to prevent truncation, ensuring a homogeneous population of untruncated mature antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the standard murine leader sequence is used for IgG light chains, then the signal peptide is recognized and bound by SRP for translocation, but N-terminal truncation occurs leading to impurities and batch variability
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence parameters of the signal peptide. Specifically, it replaces the standard murine leader sequence with alternative sequences (V-lambda or kappa leader sequences) or modifies the first three amino acids to change the cleavage site recognition parameters, thereby preventing N-terminal truncation while maintaining proper translocation and secretion functionality.
Solution Approach 2:
The patent uses copying by replacing the problematic murine leader sequence with alternative leader sequences from different antibody types (V-lambda or kappa). These alternative sequences serve as functional copies that perform the same signal peptide role (SRP binding, translocation) but with different amino acid compositions that prevent truncation of the light chain N-terminus.
2Manufacturing precision
If downstream processing is used to remove impurities, then product purity can be improved, but production time and cost increase
Solution Approach 1:
The patent applies preliminary action by preventing N-terminal truncation at the source during the antibody expression and secretion process. By modifying the signal peptide sequence beforehand, the truncation impurity is prevented from forming in the first place, eliminating the need for subsequent downstream processing steps designed to remove this specific impurity, thereby reducing production time and cost.
Solution Approach 2:
The patent converts the potential harm of signal peptide cleavage variability into a benefit by deliberately designing alternative signal peptide sequences that inherently prevent truncation. The modification of the first three amino acids or use of alternative leader sequences transforms the cleavage process from a source of impurities into a reliable, controlled process that produces homogeneous antibody products.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Prevents N-terminal truncation of IgG light chains, reducing impurities and batch variability, thereby enhancing product quality and safety by maintaining a homogeneous antibody population.
Implementation Method 1
as the nascent polypeptide emerges from the ribosome in the cytosol, the signal peptide binds to the signal recognition particle (SRP) and this complex is targeted to the translocon in the endoplasmic reticulum
Implementation Method 2
as the polypeptide is translocated from the cytosol across the membrane into the ER, the signal peptide itself is cleaved off by the signal peptidase so that the signal peptide is not part of the mature protein
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
We discovered that recombinant antibody light chains having a murine secretory leader sequence and an SYE motif at the N-terminus are truncated during post-translational processing. This disclosure provides two protein engineering solutions: to alter the SYE amino acid sequence of the Lc N-terminus to other alternatives; or to change the secretory leader peptide sequence. We have shown that both of these solutions are effective for preventing N-terminal light chain truncation.